Daclatasvir (Daklinza®) is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4).
Rapid Review
| Commenced | Completed | Outcome |
| 05/08/2014 | 12/09/2014 | Full Pharmacoeconomic Evaluation Recommended. |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 01/12/2014 | 29/05/2015 | Reimbursement recommended for certain subgroups |